22
Participants
Start Date
March 15, 2022
Primary Completion Date
August 6, 2024
Study Completion Date
August 27, 2024
Niraparib
Eligible participants will receive daily dosing of Niraparib.
Gettysburg Cancer Center, Gettysburg
The Center for Cancer and Blood Disorders - Maryland, Bethesda
Maryland Oncology Hematology, Rockville
Frederick Health, Frederick
Inova Schar Institute, Fairfax
Hematology Oncology Associates of Fredericksburg, Fredericksburg
Virginia Cancer Institute, Richmond
Virginia Cancer Institute, Richmond
Novant Health Inc. - Winston-Salem, Winston-Salem
Southeastern Medical Oncology Center, Goldsboro
Novant Health Inc. - Charlotte, Charlotte
Bon Secours - St. Francis Cancer Center, Greenville
University Cancer & Blood Center, Athens
Cancer Specialists of North Florida, Jacksonville
Holy Cross, Fort Lauderdale
Ocala Community Cancer Center, Ocala
Vanderbilt University, Nashville
Baptist Cancer Center, Memphis
OhioHealth, Columbus
The Toledo Clinic, Toledo
University Hospitals Seidman, Cleveland
Cleveland Clinic - Taussig Cancer Center, Cleveland
Aultman Medical Group, Canton
TriHealth, Cincinnati
Community Health Network, Indianapolis
Goshen Health, Goshen
Beacon Health System, South Bend
Fort Wayne Medical Oncology and Hematology, Fort Wayne
Sparrow Health, Lansing
SSM Health, Madison
ThedaCare, Appleton
Avera Cancer Institute, Sioux Falls
Sanford Health, Sioux Falls
Northwest Oncology & Hematology, Rolling Meadows
Rush University Medical Center, Chicago
Mosaic Life Care, Saint Joseph
Central Care Cancer Center, Bolivar
Oncology Hematology Associates, Springfield
Nebraska Cancer Specialists, Omaha
Pontchartrain Cancer Center, Hammond
Highlands Oncology, Springdale
Oklahoma Cancer Specialists, Tulsa
Mary Crowley Cancer Research, Dallas
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
The University of Texas Southwestern Medical Center, Dallas
Texas Oncology - Paris Cancer Center, Paris
Texas Oncology - Longview Cancer Center, Longview
Texas Oncology - Tyler Pharmacy, Tyler
Texas Oncology - Palestine Cancer Center, Palestine
Oncology Consultants, Houston
Lumi Research, Sugar Land
Texas Oncology - Austin Midtown, Austin
Texas Oncology - Austin Central Pharmacy, Austin
Texas Oncology - South Austin, Austin
Utah Cancer Specialists, Salt Lake City
Community Cancer Trials of Utah, Ogden
Yuma Regional Medical Center, Yuma
OptumCare Cancer Care, Las Vegas
University of California Los Angeles, Los Angeles
Cancer and Blood Specialty Clinic, Los Alamitos
Cancer and Blood Specialty, Los Alamitos
MemorialCare, Long Beach
Sharp Healthcare, San Diego
Memorial Care Medical Center, Fountain Valley
St Joseph Heritage Health - Fullerton, Fullerton
Ventura County Hematology Oncology Specialists, Oxnard
Ridley-Tree Cancer Center, Santa Barbara
St Joseph Health Medical Group - Napa, Napa
St Joseph Health Medical Group - Santa Rosa, Santa Rosa
Hawaii Cancer Care, Honolulu
Oregon Oncology Specialists, Salem
PeaceHealth, Bellingham
Northwest Medical Specialties, Tacoma
University of California San Diego, La Jolla
Hartford Healthcare, Hartford
Eastern Connecticut Hematology and Oncology, Norwich
Southcoast Health, Fairhaven
New Jersey Cancer Care and Blood Disorders, Belleville
Englewood Health, Englewood
Summit Medical Group, Florham Park
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Tempus AI
INDUSTRY